Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and...
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
About this item
Full title
Author / Creator
Publisher
Durham: Research Square
Journal title
Language
English
Formats
Publication information
Publisher
Durham: Research Square
Subjects
More information
Scope and Contents
Contents
Purpose Anti-PD1 inhibitors have been approved for the treatment of recurrent or metastatic head and neck cancer (HNC), as a result of Global Phase III trials. However, the clinical outcomes of immune checkpoint inhibitors in patients who are not eligible for clinical trials or have various medical conditions have not been fully elucidated. Methods...
Alternative Titles
Full title
Clinical outcomes of immune checkpoint inhibitors for patients with recurrent or metastatic head and neck cancer: real-world data in Korea
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2539469466
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2539469466
Other Identifiers
DOI
10.21203/rs.3.rs-15497/v1
How to access this item
https://www.proquest.com/docview/2539469466?pq-origsite=primo&accountid=13902
